Quick Listen: Scrip's Five Must-Know Things

In this week's podcast edition of Five Must-Know Things: will 2022 herald more big M&A deals?; Novartis’s four R&D philosophies; new clinical holds at Gilead; Pfizer recruits new chief development officer from Roche; and Scrip asks what this year will bring in the markets, competition and business strategy areas.

audio roundup of the week's major global biopharma developments

Join us for an audio catch-up on the major events in the biopharma industry over the past business week, as reported by Scrip's global team, in this podcast version of Five Must-Know Things.

This episode covers insights for the business week ended 4 February 2022, including: will 2022 herald more big M&A deals?; Novartis AG’s four R&D philosophies; new clinical holds at Gilead Sciences, Inc.; Pfizer Inc. recruits new chief development officer from Roche Holding AG; and Scrip asks what this year will bring in the markets, competition and business strategy areas.

This and all our other podcasts are available on the Informa Pharma Intelligence channel on Apple Podcasts, Google Podcasts, SoundCloud, TuneIn and Spotify Podcasts, and via smart speakers if one of these platforms has been set up as your default podcast provider.  

Stories mentioned in this episode:

(Also see "A Biopharma M&A Bonanza In 2022? Analysts Pick Top Targets And Likely Buyers" - Scrip, 2 Feb, 2022.)

 

(Also see "Novartis’s John Tsai On The Four Philosophies Driving R&D" - Scrip, 31 Jan, 2022.)

(Also see "Magrolimab Falls Off The Fast Track As Gilead Reveals New Clinical Holds" - Scrip, 1 Feb, 2022.)

(Also see "Pfizer Recruits Chief Development Officer William Pao From Roche R&D Team" - Scrip, 1 Feb, 2022.)

(Also see "Scrip Asks...What Does 2022 Hold For Biopharma? Part 1: Markets, Competition And Business Strategy" - Scrip, 1 Feb, 2022.)

Open Media